US20190134145A1 - Method for treating cognitive dysfunction - Google Patents
Method for treating cognitive dysfunction Download PDFInfo
- Publication number
- US20190134145A1 US20190134145A1 US16/189,833 US201816189833A US2019134145A1 US 20190134145 A1 US20190134145 A1 US 20190134145A1 US 201816189833 A US201816189833 A US 201816189833A US 2019134145 A1 US2019134145 A1 US 2019134145A1
- Authority
- US
- United States
- Prior art keywords
- ang
- oligopeptide
- ile
- seq
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract description 81
- 238000000034 method Methods 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims 17
- 102000015636 Oligopeptides Human genes 0.000 claims 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010093712 alamandine Proteins 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 claims 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 abstract description 97
- 208000028698 Cognitive impairment Diseases 0.000 abstract description 36
- 239000000018 receptor agonist Substances 0.000 abstract description 35
- 229940044601 receptor agonist Drugs 0.000 abstract description 35
- 108010021281 angiotensin I (1-7) Proteins 0.000 abstract description 30
- 230000006735 deficit Effects 0.000 abstract description 20
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 15
- 210000004556 brain Anatomy 0.000 abstract description 14
- 230000002757 inflammatory effect Effects 0.000 abstract description 13
- 230000015654 memory Effects 0.000 abstract description 13
- 230000014509 gene expression Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 230000013016 learning Effects 0.000 abstract description 9
- 210000003169 central nervous system Anatomy 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000004064 dysfunction Effects 0.000 abstract description 5
- 230000016396 cytokine production Effects 0.000 abstract description 3
- 206010019280 Heart failures Diseases 0.000 description 48
- 206010007559 Cardiac failure congestive Diseases 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 29
- 208000010125 myocardial infarction Diseases 0.000 description 25
- 208000024172 Cardiovascular disease Diseases 0.000 description 20
- 238000011282 treatment Methods 0.000 description 16
- 230000007423 decrease Effects 0.000 description 14
- 230000003920 cognitive function Effects 0.000 description 13
- 208000000044 Amnesia Diseases 0.000 description 11
- 208000026139 Memory disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000006984 memory degeneration Effects 0.000 description 11
- 208000023060 memory loss Diseases 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000002980 postoperative effect Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- -1 semisolids Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 9
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000006886 spatial memory Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 3
- 206010012218 Delirium Diseases 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 230000008455 cerebrovascular function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DUEUCUPESSMDMI-VVKHCXNMSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 DUEUCUPESSMDMI-VVKHCXNMSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 108010075470 AT4 receptor Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- LJXGOQOPNPFXFT-JWRYNVNRSA-N angiotensin (1-9) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 LJXGOQOPNPFXFT-JWRYNVNRSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000008801 hippocampal function Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to compositions and methods for the treatment of cognitive impairment or dysfunction.
- the present invention relates to the use of angiotensin-(1-7) receptor agonist to treat cognitive dysfunction.
- Cognitive dysfunction or impairment is a common neurological complication of congestive heart failure (“CHF”) and post cardiac surgery affecting approximately 50-70% of patients at hospital discharge and 20-40% of patients six months after surgery.
- CHF congestive heart failure
- the occurrence of CHF and postoperative cognitive dysfunction is associated with increased duration of hospitalization and impaired long-term quality of life. Without being bound by any theory, it is believed that in general any clinical condition associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species in central nervous system, in particular in the brain, can lead to cognitive dysfunction.
- compositions and methods for treating cognitive dysfunction by administering an angiotensin-(1-7) receptor agonist.
- Compositions and methods of the invention can be used to treat cognitive impairment or dysfunction (1) associated with pre- and/or post-surgery dementia, or (2) observed in patients with congestive heart failure (CHF), cardiovascular disease, or hypertension.
- CHF congestive heart failure
- the terms “treating” and “treatment” of cognitive dysfunction or impairment refer to: (1) preventing cognitive dysfunction from occurring, i.e., causing the clinical symptoms of cognitive dysfunction not to develop in a subject that may be or predisposed to developing cognitive dysfunction or impairment but does not yet experience or display symptoms of cognitive dysfunction or impairment; (2) inhibiting cognitive dysfunction of impairment, i.e., arresting or reducing the development of cognitive dysfunction or impairment or its clinical symptoms; or (3) relieving cognitive dysfunction or impairment, i.e., causing regression of cognitive dysfunction or impairment or its clinical symptoms.
- compositions and methods of the invention are useful in treating cognitive dysfunction or impairment in a subject whose cognitive dysfunction or impairment is clinically associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species in the central nervous system, in particular the brain.
- cognitive dysfunction or impairment is clinically associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species in the central nervous system, in particular the brain.
- the term “clinically associated” refers to the root cause or underlying cause of cognitive dysfunction or any other clinical condition that when ameliorated results in reduction, prevention, treatment or reversal of cognitive dysfunction.
- Exemplary clinical conditions associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species that can cause cognitive dysfunction or impairment include, but are not limited to, circulatory compromise, cardiovascular disease, hypertension, hypotension, congestive heart failure, stroke, embolism, surgery (e.g., postoperative recovery condition), dementia, Alzheimer's disease, disease related cognitive impairment, trauma related cognitive impairment, age-related dementia, postoperative related delirium and/or increase in inflammatory cytokine and/or increase in reactive oxygen species within the central nervous system of said subject or a combination thereof.
- the composition of the invention includes a peptidic angiotensin-(1-7) receptor agonist, a non-peptidic angiotensin-(1-7) receptor agonist, or a mixture thereof.
- the composition of the invention comprises angiotensin-(1-7) (i.e., “Ang-(1-7)”) peptide or a derivative thereof.
- Ang-(1-7) refers to a homolog or an analog of Ang-(1-7).
- Exemplary derivatives of Ang-(1-7) include, but are not limited to:
- Non-peptidic Ang-(1-7) receptor agonists as well as other peptidic angiotensin-(1-7) receptor agonists are known to one skilled in the art or can readily be identified using any one of the known assay methods. See, for example, U.S. Pat. Nos. 6,984,660; and 8,383,772, PCT Patent Publication Nos. WO 2009/100513; WO 2013/010241; WO 2006/128266; WO 2010/009524; and WO 02/072569, all of which are incorporated herein by reference in their entirety.
- a method for treating cognitive dysfunction and/or memory loss due to a clinical condition associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject.
- Such method includes administering a therapeutically effective amount of an angiotensin-(1-7) receptor agonist to said subject in need of such a treatment to treat cognitive dysfunction and/or memory loss.
- a therapeutically effective amount means the amount of a compound or a composition that, when administered to a subject to treat cognitive dysfunction and/or memory loss, is sufficient to effect such treatment for cognitive dysfunction and/or memory loss.
- the “therapeutically effective amount” will vary depending on the compound or the composition, and the severity of cognitive dysfunction and/or memory loss, and the age, weight, etc., of the subject to be treated.
- said angiotensin-(1-7) receptor agonist is an angiotensin-(1-7) Mas receptor agonist.
- said clinical condition comprises circulatory compromise, cardiovascular disease, hypertension, hypotension, congestive heart failure, stroke, embolism, surgery (e.g., postoperative recovery condition), dementia, Alzheimer's disease, disease related cognitive impairment, trauma related cognitive impairment, age-related dementia, postoperative related delirium and/or increase in inflammatory cytokine and/or increase in reactive oxygen species within the central nervous system of said subject or a combination thereof.
- said angiotensin-(1-7) receptor agonist comprises a peptidic angiotensin-(1-7) receptor agonist, a non-peptidic angiotensin-(1-7) receptor agonist, or a combination thereof.
- said angiotensin-(1-7) receptor agonist comprises angiotensin-(1-7) or a derivative thereof.
- FIG. 1 shows the effects of Ang-(1-7) systemic administration on object recognition impairment observed following 8 weeks of congestive heart failure.
- Mice were 12 weeks post MI or sham surgery.
- Six mice were MI+Ang(1-7); three mice were MI+saline; and four mice were Sham+Ang (1-7).
- Alzet pumps with either Ang(1-7) or saline were implanted sq 3 weeks prior to NOR test.
- Novel object recognition test was performed 3 weeks post pump implant.
- a positive score indicates more time spent with the novel object, a negative score indicates more time spent with the familiar object, and a zero score indicates a null preference.
- FIG. 2 shows the effects of Ang-(1-7) systemic administration on spatial memory as tested by the Morris water maze task.
- FIG. 3 shows the summary effects of 1 ⁇ M Ang-(1-7) inhibition of reactive oxygen production in neurons.
- Some aspects of the invention are based on the discovery by the present inventors that cognitive dysfunction and/or memory loss can be treated by administering Ang-(1-7) receptor agonist.
- the present inventors have discovered that in a mouse model of CHF induced cognitive decline, administration of Ang-(1-7) rescued the cognitive impairment post 12 weeks after myocardial infarction (MI).
- MI myocardial infarction
- Angiotensin-(1-7) is an endogenous peptide, some of which are derived from Angiotensin II conversion via angiotensin converting enzyme 2 (ACE2), and from angiotensin I by a number of peptidases.
- ACE2 angiotensin converting enzyme 2
- Ang-(1-7) are known inter alfa to activate Mas receptor. Increases in circulating Ang-(1-7) has been reported to increase in patients and animal models following administration of ACE inhibitors due to the increase in Angiotensin I which results in increased Angiotensin I conversion to Ang-(1-7).
- Ang-(1-7) has been shown to decrease inflammation and oxidative stress in both the heart and brain in preclinical studies.
- Cognitive dysfunction is a common neurological complication of a wide variety of clinical conditions including, but not limited to, congestive heart failure and post cardiac surgery.
- the occurrence of CHF and postoperative cognitive dysfunction is associated with increased duration of hospitalization and impaired long-term quality of life.
- Renin Angiotensin System Aging, Heart Failure and Cognitive Function: Some studies have shown that elderly patients in heart failure and hypertension are known to have hospital readmission rates ranging from 40 to 50% within 6 months. It has been suggested that the high readmission rates are due, at least in part, to patient's non-compliance with therapy due to increased cognitive impairment. The incidence of cognitive impairment is particularly high in cardiovascular disease and congestive heart failure patients with 30% to 80% of patients being diagnosed with some degree of cognitive loss. To date, there is no known therapy for the prevention or treatment of postoperative cognitive dysfunction or impairment or cognitive dysfunction or impairment due to a clinical condition associated with cardiovascular disease and congestive heart failure as well as other clinical conditions described above.
- Ang-(1-7) and the Brain Recently, it has become recognized that RAS involves two separate enzymatic pathways that provide a physiological counterbalance of two related peptides acting at distinct receptors.
- the well described ACE -AngII-AT1R system is thought to be physiologically opposed and balanced by the ACE2-Ang-(1-7)-Mas receptor system.
- AngII activation of AT1 receptors increases reactive oxygen species (“ROS”) and inflammation while Ang-(1-7) and Mas receptor activation decrease ROS and inflammation.
- ROS reactive oxygen species
- the role of ACE2 in the modulation of central brain function has been shown to inhibit central AngII induced hypertension by increasing Ang-(1-7) activation of the Mas receptor, increase NO release and, in endothelial cells, decrease ROS formation.
- Ang-(1-7) are produced from ACE2 cleavage of AngII.
- Ang-(1-7) has been shown to increase NO in the brain via activation of both the Mas receptor and AT2R.
- ACE2 over expression of ACE2 in the paraventricular nucleus of ACE2 knockout mice, reduced Ang II mediated oxidative stress.
- Ang-(1-7) activation of Mas receptors has been shown to directly increase intracellular NO and attenuated Ang II activation of ROS.
- ROS and NADPH reactive oxygen species
- the hippocampus is also known to express ACE 2 and the Ang-(1-7) Mas receptor.
- Ang-(1-7) and the Mas receptor are important for normal object recognition processing and blockade of the Mas receptor in the hippocampus impairs object recognition.
- Ang-(1-7) facilitates LTP in CA1 cells and this effect is blocked by antagonism of the Mas receptor.
- no studies have been conducted to determine the role of ACE2 in cognition and its changes during aging.
- the cellular mechanisms regarding the hippocampus ACE2/Ang-(1-7)/Mas receptor axis is currently unknown.
- a method for treating cognitive dysfunction and/or memory loss in a subject includes administering a therapeutically effective amount of an angiotensin-(1-7) receptor agonist to a subject in need of such a treatment.
- said cognitive dysfunction is and/or memory loss is associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of the subject.
- said cognitive dysfunction and/or memory loss is associated with cognitive impairment that occur in circulatory compromise, congestive heart failure, postoperative recovery, dementia, Alzheimer's disease, disease related cognitive impairment, and/or trauma related cognitive impairment.
- said cognitive dysfunction and/or memory loss is associated with circulatory compromise, cardiovascular disease, hypertension, hypotension, congestive heart failure, stroke, embolism, surgery, dementia, Alzheimer's disease, disease related cognitive impairment, trauma related cognitive impairment, age-related dementia, postoperative related delirium and/or increase in inflammatory cytokine and/or increase in reactive oxygen species within the central nervous system of said subject or a combination thereof.
- Exemplary Ang-(1-7) receptor agonists that are useful in the present invention include, but are not limited to, a peptidic angiotensin-(1-7) receptor agonist, a non-peptidic angiotensin-(1-7) receptor agonist, or a mixture thereof.
- the composition of the invention comprises angiotensin-(1-7) peptide or a derivative thereof.
- “A derivative” of Ang-(1-7) refers to a homolog or an analog of Ang-(1-7).
- compositions comprising an angiotensin-(1-7) receptor agonist that can be used to treat cognitive dysfunction or impairment in a subject.
- the present invention provides a composition to inhibit the decline in cognitive function and/or memory in an individual.
- Compositions and methods of the invention can be used to prevent or even reverse decline in cognitive ability.
- a method for improving cognitive function, learning and memory or protecting from loss of cognitive function known to occur in a subject or patient following a compromised circulatory function such as congestive heart failure or in post-operative patients.
- a compromised circulatory function such as congestive heart failure or in post-operative patients.
- the present inventors have discovered that administration of a therapeutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist improves cognitive function, learning and memory or protects from loss of cognitive function known to occur in following a compromised circulatory function such as congestive heart failure or in post-operative patients.
- ang-(1-7) receptor agonist increases the expression of genes involved in learning and memory, improves cerebrovascular function, and/or decreases expression of brain inflammatory related genes.
- some embodiments of the invention provide a method for increasing the expression of a gene involved in learning and memory or improving cerebrovascular function or decreasing the expression of a brain inflammatory related gene by administering a therapeutically effective amount of Ang-(1-7) receptor agonist to a subject.
- the present invention provides a treatment for the prevention of cognitive dysfunction or impairment and/or improvement in cognitive function that is associated with clinical conditions described herein including, but not limited to, cardiovascular disease, congestive heart failure and postoperative related decline in cognitive function.
- the invention provides a method for treating cognitive dysfunction or impairment by administering a therapeutically effective amount of an Ang-(1-7) receptor agonist.
- the Ang-(1-7) receptor agonist selectively targets the brain tissue, often with high efficacy, to either reduce cellular signals that promote cognitive impairment or to increase cellular signals that promote cognitive function.
- the Ang-(1-7) receptor agonist is Ang-(1-7) peptide or a derivative thereof.
- the composition comprises a compound that increases plasma, tissue or cellular Ang-(1-7) level.
- the composition comprises a compound that inhibits or reduces neuronal reactive oxygen species production and/or NAD(P)H related enzyme expression.
- the angiotensin-(1-7) receptor agonist comprises angiotensin-(1-7) peptide.
- the present invention includes pharmaceutical compositions comprising at least one Ang-(1-7) receptor agonist or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
- composition of the invention is administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
- Suitable dosage ranges are typically 1-500 mg daily, typically 1-100 mg daily, and often 1-30 mg daily, depending on numerous factors, e.g., the severity of the cognitive impairment, the age and relative health of the subject, the potency of the Ang-(1-7) receptor agonist used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
- One of ordinary skill in the art of treating such diseases is typically able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of the invention.
- compositions of the invention are administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), nasal, pulmonary or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
- oral including buccal and sub-lingual
- nasal including buccal and sub-lingual
- pulmonary or parenteral including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous
- Typical manner of administration is generally oral or parenteral using a convenient dosage regimen which can be adjusted according to the degree of affliction.
- compositions of the invention can include one or more conventional adjuvants, carriers, or diluents, and can be placed into the form of pharmaceutical compositions and unit dosages.
- the pharmaceutical compositions and unit dosage forms can be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms can contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
- the pharmaceutical compositions can be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of sterile injectable solutions for parenteral use.
- Formulations containing about 100 milligram of active ingredient or, more broadly, about 1 to about 1,000 milligrams, per tablet, are accordingly suitable representative unit dosage forms.
- compositions of the invention can be formulated in a wide variety of oral administration dosage forms.
- the pharmaceutical compositions and dosage forms can comprise an Ang-(1-7) receptor agonist or pharmaceutically acceptable salts thereof as the active component.
- the pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
- the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound.
- Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
- cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral administration.
- liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
- Emulsions can be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
- Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents.
- Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
- Solid form preparations include solutions, suspensions, and emulsions, and can contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- Ang-(1-7) receptor agonists can also be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and can be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
- parenteral administration e.g., by injection, for example bolus injection or continuous infusion
- the compositions of the invention can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
- oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and can contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
- the active ingredient can be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
- compositions of the invention can also be formulated for nasal administration.
- the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
- the formulations can be provided in a single or multidose form. In the latter case of a dropper or pipette, this can be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this can be achieved for example by means of a metering atomizing spray pump.
- compositions of the invention can be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
- the compositions will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size can be obtained by means known in the art, for example by micronization.
- the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas.
- CFC chlorofluorocarbon
- the aerosol can conveniently also contain a surfactant such as lecithin.
- the dose of Ang-(1-7) receptor agonist can be controlled by a metered valve.
- the active ingredients can be provided in a form of a dry powder, for example, a powder mix of the composition in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
- the powder carrier typically forms a gel in the nasal cavity.
- the powder composition can be presented in unit dose form, for example, in capsules or cartridges of e.g., gelatine or blister packs from which the powder can be administered by means of an inhaler.
- compositions of the invention can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
- the compositions of the invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the ang-(1-7) receptor agonist is necessary or desired and when patient compliance with a treatment regimen is crucial.
- Compositions in transdermal delivery systems are frequently attached to a skin-adhesive solid support.
- the compositions of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one).
- Sustained release delivery systems can be inserted subcutaneously into the subdermal layer by surgery or injection.
- the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
- the pharmaceutical preparations are typically in unit dosage forms.
- the preparation is often subdivided into unit doses containing appropriate quantities of ang-(1-7) receptor agonist.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- FIG. 1 shows the effects of systemically administered Ang-(1-7) on object recognition impairment following 8 weeks of congestive heart failure.
- Myocardial infarction and subsequent CHF was induced by ligation of the left coronary artery.
- discrimination ratios were calculated from the time spent exploring the novel versus familiar object during the test phase.
- FIG. 2 shows the effects of systemic administration of Ang-(1-7) on spatial memory as tested by the Morris water maze task.
- the controls and CHF mice groups performed similarly on the Morris water task. Myocardial infarction and subsequent CHF was induced by ligation of the left coronary artery.
- CHF mice had approximately 50 and 70% decline in ejection fraction as measured by echocardiography.
- FIG. 3 shows the summary effects of 1 ⁇ M Ang-(1-7) inhibition of reactive oxygen species production in neurons.
- Paraventricular neurons were isolated from 22 day old female SD rats, dissociated and cultured on round coverslips and maintained in HBSS media for at least 48 hours prior to visualization by confocal microscopy. All cells were pre-incubated in 10 nM ALDO for 48 hours and then 1.0 ⁇ M Ang-(1-7) or 1.0 ⁇ M Ang-(1-7)+10.0 ⁇ M A779 for 2 hours prior to testing with acute 1.0 ⁇ M Aldo.
- compositions and methods of the invention are useful in treating cognitive dysfunction or impairment associated with a variety of clinical conditions discussed herein.
- the invention provides a preclinical animal model of cardiovascular disease and congestive heart failure induced cognitive dysfunction.
- a total of 26, male C57B1/6J mice were randomly assigned to the control group or cardiovascular disease and congestive heart failure group.
- Myocardial infarction was induced by ligation of the left coronary artery.
- Mice were tested for changes in spatial learning memory via the Morris water task and object recognition via the standard spontaneous object recognition (SOR) task at 4 and 8 weeks post MI.
- SOR spontaneous object recognition
- mice and cardiovascular disease and congestive heart failure mice groups performed similarly on the Morris water task.
- Animals were tested over 4 days with 6 spatial trials per day.
- Angiotensin (1-7) and Mas receptor activation inhibit Aldosterone induced ROS inflammatory responses in neurons of the paraventricular nucleus (PVN).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides compositions and methods for treating cognitive impairment or dysfunction in a subject. In particular, the present invention provides a method for using a composition comprising an angiotensin-(1-7) receptor agonist to treat cognitive dysfunction or impairment that is due to a various clinical conditions including, but not limited to, those associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/987,539, filed Jan. 4, 2016, now U.S. Pat. No. 10,172,908, which is a continuation of International Patent Application No. PCT/US2014/044962, filed Jun. 30, 2014, which claims the priority benefit of U.S. Provisional Application No. 61/842,897, filed Jul. 3, 2013, which is incorporated herein by reference in its entirety.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 4, 2018, is named UAPN_001_C1_SL.txt and is 1,859 bytes in size.
- The present invention relates to compositions and methods for the treatment of cognitive impairment or dysfunction. In particular, the present invention relates to the use of angiotensin-(1-7) receptor agonist to treat cognitive dysfunction.
- Cognitive dysfunction or impairment is a common neurological complication of congestive heart failure (“CHF”) and post cardiac surgery affecting approximately 50-70% of patients at hospital discharge and 20-40% of patients six months after surgery. The occurrence of CHF and postoperative cognitive dysfunction is associated with increased duration of hospitalization and impaired long-term quality of life. Without being bound by any theory, it is believed that in general any clinical condition associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species in central nervous system, in particular in the brain, can lead to cognitive dysfunction.
- Unfortunately, there is no effective pharmacological treatment for cognitive impairment or dysfunction for CHF and postoperative patients or for any other clinical condition associated with an increase in inflammation cytokines and/or increase in reactive oxygen species in the brain.
- Accordingly, there is a need for a treatment for cognitive dysfunction in a clinical condition associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species.
- One particular aspect of the invention relates to compositions and methods for treating cognitive dysfunction by administering an angiotensin-(1-7) receptor agonist. Compositions and methods of the invention can be used to treat cognitive impairment or dysfunction (1) associated with pre- and/or post-surgery dementia, or (2) observed in patients with congestive heart failure (CHF), cardiovascular disease, or hypertension. As used herein, the terms “treating” and “treatment” of cognitive dysfunction or impairment refer to: (1) preventing cognitive dysfunction from occurring, i.e., causing the clinical symptoms of cognitive dysfunction not to develop in a subject that may be or predisposed to developing cognitive dysfunction or impairment but does not yet experience or display symptoms of cognitive dysfunction or impairment; (2) inhibiting cognitive dysfunction of impairment, i.e., arresting or reducing the development of cognitive dysfunction or impairment or its clinical symptoms; or (3) relieving cognitive dysfunction or impairment, i.e., causing regression of cognitive dysfunction or impairment or its clinical symptoms.
- More generally, compositions and methods of the invention are useful in treating cognitive dysfunction or impairment in a subject whose cognitive dysfunction or impairment is clinically associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species in the central nervous system, in particular the brain. As used herein, the term “clinically associated” refers to the root cause or underlying cause of cognitive dysfunction or any other clinical condition that when ameliorated results in reduction, prevention, treatment or reversal of cognitive dysfunction. Exemplary clinical conditions associated with an increase in inflammatory cytokines and/or increase in reactive oxygen species that can cause cognitive dysfunction or impairment include, but are not limited to, circulatory compromise, cardiovascular disease, hypertension, hypotension, congestive heart failure, stroke, embolism, surgery (e.g., postoperative recovery condition), dementia, Alzheimer's disease, disease related cognitive impairment, trauma related cognitive impairment, age-related dementia, postoperative related delirium and/or increase in inflammatory cytokine and/or increase in reactive oxygen species within the central nervous system of said subject or a combination thereof.
- In some embodiments, the composition of the invention includes a peptidic angiotensin-(1-7) receptor agonist, a non-peptidic angiotensin-(1-7) receptor agonist, or a mixture thereof. In one particular instance, the composition of the invention comprises angiotensin-(1-7) (i.e., “Ang-(1-7)”) peptide or a derivative thereof. “A derivative” of Ang-(1-7) refers to a homolog or an analog of Ang-(1-7). Exemplary derivatives of Ang-(1-7) include, but are not limited to:
-
- (i) peptides derived from Ang-(1-7);
- (ii) peptides in which one or several amino acids of the natural Ang-(1-7) sequence have been substituted by other amino acids;
- (iii) Ang-(1-7) modified at the N- and/or C-terminal end of the peptide sequence, for example, by substitution; thus, esters and amides can be considered as C-terminal derivatives;
- (iv) Ang-(1-7) peptides the modification of which prevents their destruction by proteases or peptidases, as well as to peptide-PEG-conjugates derived from the basic sequence of Ang-(1-7);
- (v) modified peptides which are derived from the chain of Ang-(1-7) and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have the desired Ang-(1-7) effects, i.e., are angiotensin-(1-7) receptor agonists;
- (vi) peptides having conservative substitutions of amino acids as compared to the natural sequence of Ang-(1-7) in one or several positions. A conservative substitution is defined as the side chain of the respective amino acid being replaced by a side chain of similar chemical structure and polarity, the side chain being derived from a genetically coded or not genetically coded amino acid. Families of amino acids of this kind having similar side chains are known in the art. They comprise for instance amino acids having basic side chains (lysins, arginins, histidine), acidic side chains (aspartic acid, glutamic acid), uncharged polar side chains (glycine, aspartamic acid, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), (3-branched side chains (threonine, valine, isoleucine) and aromatic side chains (tyrosine, phenylalanine, tryptophane, histidine). Such conservative substitutions of side chains are typically carried out in non-essential positions. In this context, an essential position in the sequence is one wherein the side chain of the relevant amino acid is of significance for its biological effect.
- Non-peptidic Ang-(1-7) receptor agonists as well as other peptidic angiotensin-(1-7) receptor agonists are known to one skilled in the art or can readily be identified using any one of the known assay methods. See, for example, U.S. Pat. Nos. 6,984,660; and 8,383,772, PCT Patent Publication Nos. WO 2009/100513; WO 2013/010241; WO 2006/128266; WO 2010/009524; and WO 02/072569, all of which are incorporated herein by reference in their entirety.
- In one particular aspect of the invention, a method is provided for treating cognitive dysfunction and/or memory loss due to a clinical condition associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject. Such method includes administering a therapeutically effective amount of an angiotensin-(1-7) receptor agonist to said subject in need of such a treatment to treat cognitive dysfunction and/or memory loss. As used herein, “a therapeutically effective amount” means the amount of a compound or a composition that, when administered to a subject to treat cognitive dysfunction and/or memory loss, is sufficient to effect such treatment for cognitive dysfunction and/or memory loss. The “therapeutically effective amount” will vary depending on the compound or the composition, and the severity of cognitive dysfunction and/or memory loss, and the age, weight, etc., of the subject to be treated.
- In some embodiments, said angiotensin-(1-7) receptor agonist is an angiotensin-(1-7) Mas receptor agonist.
- Yet in other embodiments, said clinical condition comprises circulatory compromise, cardiovascular disease, hypertension, hypotension, congestive heart failure, stroke, embolism, surgery (e.g., postoperative recovery condition), dementia, Alzheimer's disease, disease related cognitive impairment, trauma related cognitive impairment, age-related dementia, postoperative related delirium and/or increase in inflammatory cytokine and/or increase in reactive oxygen species within the central nervous system of said subject or a combination thereof.
- Still in other embodiments, said angiotensin-(1-7) receptor agonist comprises a peptidic angiotensin-(1-7) receptor agonist, a non-peptidic angiotensin-(1-7) receptor agonist, or a combination thereof.
- In other embodiments, said angiotensin-(1-7) receptor agonist comprises angiotensin-(1-7) or a derivative thereof.
-
FIG. 1 shows the effects of Ang-(1-7) systemic administration on object recognition impairment observed following 8 weeks of congestive heart failure. Mice were 12 weeks post MI or sham surgery. Six mice were MI+Ang(1-7); three mice were MI+saline; and four mice were Sham+Ang (1-7). Alzet pumps with either Ang(1-7) or saline were implanted sq 3 weeks prior to NOR test. Novel object recognition test was performed 3 weeks post pump implant. Data shown are 1st 2 min of “test phase” DRatio=(t novel−t familiar)/(t novel+t familiar). A positive score indicates more time spent with the novel object, a negative score indicates more time spent with the familiar object, and a zero score indicates a null preference. *=p<0.05, #=p<0.05. ANOVA+posthoc Turkey test. -
FIG. 2 shows the effects of Ang-(1-7) systemic administration on spatial memory as tested by the Morris water maze task. -
FIG. 3 shows the summary effects of 1 μM Ang-(1-7) inhibition of reactive oxygen production in neurons. - Some aspects of the invention are based on the discovery by the present inventors that cognitive dysfunction and/or memory loss can be treated by administering Ang-(1-7) receptor agonist. In particular, the present inventors have discovered that in a mouse model of CHF induced cognitive decline, administration of Ang-(1-7) rescued the cognitive impairment post 12 weeks after myocardial infarction (MI).
- Angiotensin-(1-7) is an endogenous peptide, some of which are derived from Angiotensin II conversion via angiotensin converting enzyme 2 (ACE2), and from angiotensin I by a number of peptidases. Ang-(1-7) are known inter alfa to activate Mas receptor. Increases in circulating Ang-(1-7) has been reported to increase in patients and animal models following administration of ACE inhibitors due to the increase in Angiotensin I which results in increased Angiotensin I conversion to Ang-(1-7). Ang-(1-7) has been shown to decrease inflammation and oxidative stress in both the heart and brain in preclinical studies.
- Cognitive dysfunction is a common neurological complication of a wide variety of clinical conditions including, but not limited to, congestive heart failure and post cardiac surgery. The occurrence of CHF and postoperative cognitive dysfunction is associated with increased duration of hospitalization and impaired long-term quality of life.
- Renin Angiotensin System: Aging, Heart Failure and Cognitive Function: Some studies have shown that elderly patients in heart failure and hypertension are known to have hospital readmission rates ranging from 40 to 50% within 6 months. It has been suggested that the high readmission rates are due, at least in part, to patient's non-compliance with therapy due to increased cognitive impairment. The incidence of cognitive impairment is particularly high in cardiovascular disease and congestive heart failure patients with 30% to 80% of patients being diagnosed with some degree of cognitive loss. To date, there is no known therapy for the prevention or treatment of postoperative cognitive dysfunction or impairment or cognitive dysfunction or impairment due to a clinical condition associated with cardiovascular disease and congestive heart failure as well as other clinical conditions described above.
- Recently, there has been considerable attention paid to the role of ACE1 blockers and AngII in age changes in memory, cardiovascular disease and congestive heart failure, Alzheimer's disease and dementia. Studies in elderly cardiovascular disease and congestive heart failure and in essentially hypertensive patients found that treatment with ACE inhibitors improved cognitive function independent of the effect on blood pressure. The mechanisms underlying these effects are thought to include decreases in brain AngII, which would decrease the known deleterious inflammatory effects of AngII on memory and hippocampus function. In addition, a decrease in AngII would attenuate AngII inhibition of acetylcholine release. In addition, it was believed by others that decrease in AngII would also increase availability of AngI conversion to Ang(1-9) and Ang-(1-7) ultimately to form Ang(2-7) and Ang(3-7) thus increasing activation of AT4 receptors, which are known to facilitate hippocampus LTP.
- Ang-(1-7) and the Brain: Recently, it has become recognized that RAS involves two separate enzymatic pathways that provide a physiological counterbalance of two related peptides acting at distinct receptors. The well described ACE -AngII-AT1R system is thought to be physiologically opposed and balanced by the ACE2-Ang-(1-7)-Mas receptor system. In the brain and other tissues, AngII activation of AT1 receptors increases reactive oxygen species (“ROS”) and inflammation while Ang-(1-7) and Mas receptor activation decrease ROS and inflammation. The role of ACE2 in the modulation of central brain function has been shown to inhibit central AngII induced hypertension by increasing Ang-(1-7) activation of the Mas receptor, increase NO release and, in endothelial cells, decrease ROS formation.
- As discussed above, some of the Ang-(1-7) are produced from ACE2 cleavage of AngII. Ang-(1-7) has been shown to increase NO in the brain via activation of both the Mas receptor and AT2R. Further, over expression of ACE2 in the paraventricular nucleus of ACE2 knockout mice, reduced Ang II mediated oxidative stress. In the kidney, Ang-(1-7) activation of Mas receptors has been shown to directly increase intracellular NO and attenuated Ang II activation of ROS. In addition, it has been shown that in older animals, there is a marked reduction of kidney ACE2 function and a loss of Ang-(1-7) compared to younger animals. The role of reactive oxygen species in age related changes in learning and memory have been extensively studied. In younger healthy animals, ROS and NADPH appear to be required for normal learning and hippocampal LTP; however, in aging animals, LTP and memory impairments were shown to be linked to increased ROS.
- The hippocampus is also known to express ACE 2 and the Ang-(1-7) Mas receptor. Recent studies in mice lacking the Mas receptor have shown that Ang-(1-7) and the Mas receptor are important for normal object recognition processing and blockade of the Mas receptor in the hippocampus impairs object recognition. Earlier studies have shown that Ang-(1-7) facilitates LTP in CA1 cells and this effect is blocked by antagonism of the Mas receptor. To date, no studies have been conducted to determine the role of ACE2 in cognition and its changes during aging. Furthermore, the cellular mechanisms regarding the hippocampus ACE2/Ang-(1-7)/Mas receptor axis is currently unknown.
- In one particular aspect of the invention, a method is provided for treating cognitive dysfunction and/or memory loss in a subject. Such a method includes administering a therapeutically effective amount of an angiotensin-(1-7) receptor agonist to a subject in need of such a treatment.
- In some embodiments, said cognitive dysfunction is and/or memory loss is associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of the subject.
- Yet in other embodiments, said cognitive dysfunction and/or memory loss is associated with cognitive impairment that occur in circulatory compromise, congestive heart failure, postoperative recovery, dementia, Alzheimer's disease, disease related cognitive impairment, and/or trauma related cognitive impairment.
- Still in other embodiments, said cognitive dysfunction and/or memory loss is associated with circulatory compromise, cardiovascular disease, hypertension, hypotension, congestive heart failure, stroke, embolism, surgery, dementia, Alzheimer's disease, disease related cognitive impairment, trauma related cognitive impairment, age-related dementia, postoperative related delirium and/or increase in inflammatory cytokine and/or increase in reactive oxygen species within the central nervous system of said subject or a combination thereof.
- Exemplary Ang-(1-7) receptor agonists that are useful in the present invention include, but are not limited to, a peptidic angiotensin-(1-7) receptor agonist, a non-peptidic angiotensin-(1-7) receptor agonist, or a mixture thereof. In one particular instance, the composition of the invention comprises angiotensin-(1-7) peptide or a derivative thereof. “A derivative” of Ang-(1-7) refers to a homolog or an analog of Ang-(1-7).
- Some aspects of the invention provide compositions comprising an angiotensin-(1-7) receptor agonist that can be used to treat cognitive dysfunction or impairment in a subject. In one embodiment, the present invention provides a composition to inhibit the decline in cognitive function and/or memory in an individual. Compositions and methods of the invention can be used to prevent or even reverse decline in cognitive ability.
- In one particular embodiment, a method is provided for improving cognitive function, learning and memory or protecting from loss of cognitive function known to occur in a subject or patient following a compromised circulatory function such as congestive heart failure or in post-operative patients. As shown in the Examples section using an appropriate animal model, the present inventors have discovered that administration of a therapeutically effective amount of angiotensin-(1-7) or angiotensin-(1-7) receptor agonist improves cognitive function, learning and memory or protects from loss of cognitive function known to occur in following a compromised circulatory function such as congestive heart failure or in post-operative patients.
- Administration of a therapeutically effective amount of ang-(1-7) receptor agonist increases the expression of genes involved in learning and memory, improves cerebrovascular function, and/or decreases expression of brain inflammatory related genes. Thus, some embodiments of the invention provide a method for increasing the expression of a gene involved in learning and memory or improving cerebrovascular function or decreasing the expression of a brain inflammatory related gene by administering a therapeutically effective amount of Ang-(1-7) receptor agonist to a subject.
- In some aspects, the present invention provides a treatment for the prevention of cognitive dysfunction or impairment and/or improvement in cognitive function that is associated with clinical conditions described herein including, but not limited to, cardiovascular disease, congestive heart failure and postoperative related decline in cognitive function. In some embodiments, the invention provides a method for treating cognitive dysfunction or impairment by administering a therapeutically effective amount of an Ang-(1-7) receptor agonist. In some instances, the Ang-(1-7) receptor agonist selectively targets the brain tissue, often with high efficacy, to either reduce cellular signals that promote cognitive impairment or to increase cellular signals that promote cognitive function.
- In other embodiments, the Ang-(1-7) receptor agonist is Ang-(1-7) peptide or a derivative thereof.
- Still in other embodiments, the composition comprises a compound that increases plasma, tissue or cellular Ang-(1-7) level.
- Yet in other embodiments, the composition comprises a compound that inhibits or reduces neuronal reactive oxygen species production and/or NAD(P)H related enzyme expression.
- In one particular embodiment, the angiotensin-(1-7) receptor agonist comprises angiotensin-(1-7) peptide.
- Administration and Pharmaceutical Composition: The present invention includes pharmaceutical compositions comprising at least one Ang-(1-7) receptor agonist or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
- In general, the composition of the invention is administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, typically 1-100 mg daily, and often 1-30 mg daily, depending on numerous factors, e.g., the severity of the cognitive impairment, the age and relative health of the subject, the potency of the Ang-(1-7) receptor agonist used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved. One of ordinary skill in the art of treating such diseases is typically able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of the invention.
- Typically, compositions of the invention are administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), nasal, pulmonary or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. Typical manner of administration is generally oral or parenteral using a convenient dosage regimen which can be adjusted according to the degree of affliction.
- Compositions of the invention can include one or more conventional adjuvants, carriers, or diluents, and can be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms can be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms can contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions can be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of sterile injectable solutions for parenteral use. Formulations containing about 100 milligram of active ingredient or, more broadly, about 1 to about 1,000 milligrams, per tablet, are accordingly suitable representative unit dosage forms.
- The compositions of the invention can be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms can comprise an Ang-(1-7) receptor agonist or pharmaceutically acceptable salts thereof as the active component. The pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral administration.
- Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions can be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and can contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- Ang-(1-7) receptor agonists can also be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and can be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions of the invention can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and can contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
- The compositions of the invention can also be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations can be provided in a single or multidose form. In the latter case of a dropper or pipette, this can be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this can be achieved for example by means of a metering atomizing spray pump.
- The compositions of the invention can be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compositions will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size can be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol can conveniently also contain a surfactant such as lecithin. The dose of Ang-(1-7) receptor agonist can be controlled by a metered valve. Alternatively, the active ingredients can be provided in a form of a dry powder, for example, a powder mix of the composition in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier typically forms a gel in the nasal cavity. The powder composition can be presented in unit dose form, for example, in capsules or cartridges of e.g., gelatine or blister packs from which the powder can be administered by means of an inhaler.
- When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compositions of the invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the ang-(1-7) receptor agonist is necessary or desired and when patient compliance with a treatment regimen is crucial. Compositions in transdermal delivery systems are frequently attached to a skin-adhesive solid support. The compositions of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one). Sustained release delivery systems can be inserted subcutaneously into the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
- The pharmaceutical preparations are typically in unit dosage forms. In such form, the preparation is often subdivided into unit doses containing appropriate quantities of ang-(1-7) receptor agonist. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
- Other suitable pharmaceutical carriers and their formulations are described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pa.
- Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting. In the Examples, procedures that are constructively reduced to practice are described in the present tense, and procedures that have been carried out in the laboratory are set forth in the past tense.
- Ang-(1-7) Reverses Congestive Heart Failure Reduction in Object Recognition Memory:
FIG. 1 shows the effects of systemically administered Ang-(1-7) on object recognition impairment following 8 weeks of congestive heart failure. Myocardial infarction and subsequent CHF was induced by ligation of the left coronary artery. By week 4 and week 8 post MI, CHF mice (n=15) had approximately 50 and 70% decline in ejection fraction as measured by echocardiography. For the object recognition SOR test at 8 weeks post MI, discrimination ratios were calculated from the time spent exploring the novel versus familiar object during the test phase. The CHF mice (n=5) had significantly lower discrimination ratios compared to the shams (−0.43+0.05 vs +0.16±0.1, F(1,7)=27.4, p=0.001, ANOVA). At 8 weeks post MI, a subgroup of CHF mice (n=6) and controls (n=4) were given 50 mcg/kg/hr Angiotensin (1-7) or saline subcutaneously for 4 weeks and then cognitive function was retested. Following 3 weeks of treatment with systemic Ang-(1-7), SOR discrimination ratios for CHF mice (n=6) were similar to controls (n=3) (+0.43±0.1 vs +0.25±0.2) but were significantly different to the CHF mice treated with saline (n=4, −0.21±0.1, F (2,10)=6.0, p=0.01, ANOVA). - Ang-(1-7) Reverses Congestive Heart Failure Reduction in Spatial Memory:
FIG. 2 shows the effects of systemic administration of Ang-(1-7) on spatial memory as tested by the Morris water maze task. Prior to MI, the controls and CHF mice groups performed similarly on the Morris water task. Myocardial infarction and subsequent CHF was induced by ligation of the left coronary artery. By week 4 and week 8 post MI, CHF mice had approximately 50 and 70% decline in ejection fraction as measured by echocardiography. At both 4 (n=10) and 8 weeks (n=9) post MI, the mean performance of the CHF mice in the Morris water task was significantly worse than the performance of the controls (n=4). Animals were tested over 4 days with 6 spatial trials per day. The corrected integrated path length (CIPL) at both 4 and 8 weeks post MI was significantly decreased on day 4 (−66.9±1.6%, −65.3±1.1% respectively, compared to control, (F (1,75) =9.11, p=0.003, ANOVA, 4 week post MI). At 8 weeks post MI, a subgroup of CHF mice (n=6) and controls (n=4) were given 50 mcg/kg/hr Angiotensin (1-7) or saline subcutaneously for 4 weeks and then cognitive function was retested. Mice receiving Ang-(1-7) showed a significant improvement on object recognition memory on the first day of testing. - Ang-(1-7) Inhibits Production of Reactive Oxygen in Neurons:
FIG. 3 shows the summary effects of 1 μM Ang-(1-7) inhibition of reactive oxygen species production in neurons. Paraventricular neurons were isolated from 22 day old female SD rats, dissociated and cultured on round coverslips and maintained in HBSS media for at least 48 hours prior to visualization by confocal microscopy. All cells were pre-incubated in 10 nM ALDO for 48 hours and then 1.0 μM Ang-(1-7) or 1.0 μM Ang-(1-7)+10.0 μM A779 for 2 hours prior to testing with acute 1.0 μM Aldo. To measure ROS, changes in the ethidium fluorescence were measured which is directly proportional to the oxidation of dihydroethidium (DHE) by ROS. The cells were loaded with DHE (20 μM) added to the cell culture media for 1 h and then placed in a chamber for microscopic visualization of fluorescence. One-way ANOVAs for the experimental groups response to acute Aldo was determined. After establishing a significant ANOVA, post-hoc analyses were performed with Tukey multiple comparison tests between pairs of mean change scores. All data are expressed as means±SE. Statistical significance was set at P<0.05. - Perfusion with 1.0 μM ALDO increased ROS (D=113.4+28%) in the PVN neurons. In cells pre-incubated in Ang-(1-7), ALDO increase in ROS was significantly inhibited (D=6.4+27%). Pre-incubation in Ang-(1-7)+A779, restored the ALDO increase in ROS (Delta=105.9+9%). Change in ROS production was standardized relative to control state prior to ALDO treatment during ACSF incubation. ANOVA followed by Tukey's post hoc test was used for statistical comparisons between control and ALDO treatment. Differences were considered statistically significant when p≤0.05. * indicates p≤0.05.
- Patients with congestive heart failure or cardiovascular disease have a much higher probability of mortality if they are concomitantly diagnosed with cognitive decline and memory loss. Furthermore, these patients have hospital readmission rates ranging from 40 to 50% within 6 months that are due, in part, to patient's non-compliance with therapy as a result of cognitive impairment. As discussed herein, compositions and methods of the invention are useful in treating cognitive dysfunction or impairment associated with a variety of clinical conditions discussed herein.
- In addition, the invention provides a preclinical animal model of cardiovascular disease and congestive heart failure induced cognitive dysfunction. A total of 26, male C57B1/6J mice were randomly assigned to the control group or cardiovascular disease and congestive heart failure group. Myocardial infarction was induced by ligation of the left coronary artery. By week 4 and week 8 post MI, cardiovascular disease and congestive heart failure mice (n=15) had approximately 50 and 70% decline in ejection fraction as measured by echocardiography. Mice were tested for changes in spatial learning memory via the Morris water task and object recognition via the standard spontaneous object recognition (SOR) task at 4 and 8 weeks post MI. At 8 weeks post MI, a subgroup of cardiovascular disease and congestive heart failure mice (n=6) and the control mice (n=4) were given 50 mcg/kg/hr Angiotensin (1-7) or saline subcutaneously for 4 weeks and then cognitive function was retested.
- Prior to MI, the control mice and cardiovascular disease and congestive heart failure mice groups performed similarly on the Morris water task. At both 4 (n=10) and 8 weeks (n=9) post MI, the mean performance of the cardiovascular disease and congestive heart failure mice in the Morris water task was significantly worse than the performance of the control mice (n=4). Animals were tested over 4 days with 6 spatial trials per day. The corrected integrated path length (CIPL) at both 4 and 8 weeks post MI was significantly decreased on day 4 (−66.9 ±1.6%, −65.3±1.1% respectively, compared to control, (F (1,75)=9.11, p=0.003, ANOVA, 4 week post MI). For the object recognition SOR test at 8 weeks post MI, when discrimination ratios were calculated from the time spent exploring the novel versus familiar object during the test phase, the cardiovascular disease and congestive heart failure mice (n=5) had significantly lower discrimination ratios compared to the control mice (−0.43+0.05 vs +0.16±0.1, F(1,7)=27.4, p=0.001, ANOVA). Following 3 weeks treatment with systemic Ang-(1-7), cardiovascular disease and congestive heart failure mice (n=6) SOR discrimination ratios were similar to the control mice (n=3) (+0.43±0.1 vs +0.25±0.2) and significantly different compared to the cardiovascular disease and congestive heart failure mice treated with saline (n=4, −0.21+0.1, F (2,10) =6.0, p=0.01, ANOVA). Interestingly, ejection fraction was not significantly impacted by Ang-(1-7) treatment. These results show that the preclinical mouse model of cardiovascular disease and congestive heart failure exhibit both spatial memory and object recognition dysfunction and that this cognitive dysfunction is attenuated by treatment with systemic Ang-(1-7). (JK R01HL098256, KO2HL105799, C B McKnight Brain Research Foundation). Angiotensin (1-7) and Mas receptor activation inhibit Aldosterone induced ROS inflammatory responses in neurons of the paraventricular nucleus (PVN).
- The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. Although the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter.
Claims (16)
1. An oligopeptide selected from the group consisting of:
2. The oligopeptide of claim 1 , wherein the oligopeptide is Asp-Arg-Val-Ser-Ile-His-Pro (SEQ ID NO: 1).
3. The oligopeptide of claim 1 , wherein the oligopeptide is Asp-Arg-Val-Tyr-Ile-His-Cys (SEQ ID NO: 2).
4. The oligopeptide of claim 1 , wherein the oligopeptide is Asp-Arg-Val-Ser-Ile-His-Cys (SEQ ID NO: 3).
5. The oligopeptide of claim 1 , wherein the oligopeptide is Asp-Arg-NorLeu-Tyr-Ile-His-Pro (SEQ ID NO: 4).
6. The oligopeptide of claim 1 , wherein the oligopeptide is Arg-Val-Tyr-Ile-His-Pro-Phe (SEQ ID NO: 6).
7. The oligopeptide of claim 1 , wherein the oligopeptide is Ala-Arg-Val-Tyr-Ile-His-Pro (SEQ ID NO: 7).
8. The oligopeptide of claim 1 , wherein the oligopeptide further comprises a polyethylene glycol polymer.
9. A pharmaceutical formulation comprising the oligopeptide of claim 1 and at least one pharmaceutically-acceptable carrier.
10. The pharmaceutical formulation of claim 9 , wherein the pharmaceutical formulation is formulated for intravenous, intraarterial, intramuscular, intrathecal, or subcutaneous injection.
11. The formulation of claim 9 , wherein the pharmaceutical formulation is formulated for insufflation or intranasal administration.
12. The formulation of claim 9 , wherein the pharmaceutical formulation is formulated as an aerosol or a dry powder.
13. A pharmaceutical formulation comprising the oligopeptide of claim 8 .
14. The pharmaceutical formulation of claim 13 , wherein the pharmaceutical formulation is formulated for intravenous, intraarterial, intramuscular, intrathecal, or subcutaneous injection.
15. The formulation of claim 13 , wherein the pharmaceutical formulation is formulated for insufflation or intranasal administration.
16. The formulation of claim 13 , wherein the pharmaceutical formulation is formulated as an aerosol or a dry powder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/189,833 US20190134145A1 (en) | 2013-07-03 | 2018-11-13 | Method for treating cognitive dysfunction |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361842897P | 2013-07-03 | 2013-07-03 | |
PCT/US2014/044962 WO2015002903A1 (en) | 2013-07-03 | 2014-06-30 | Method for treating cognitive dysfunction |
US14/987,539 US10172908B2 (en) | 2013-07-03 | 2016-01-04 | Method for treating cognitive dysfunction |
US16/189,833 US20190134145A1 (en) | 2013-07-03 | 2018-11-13 | Method for treating cognitive dysfunction |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/987,539 Continuation US10172908B2 (en) | 2013-07-03 | 2016-01-04 | Method for treating cognitive dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190134145A1 true US20190134145A1 (en) | 2019-05-09 |
Family
ID=52144145
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/987,539 Active US10172908B2 (en) | 2013-07-03 | 2016-01-04 | Method for treating cognitive dysfunction |
US16/189,833 Abandoned US20190134145A1 (en) | 2013-07-03 | 2018-11-13 | Method for treating cognitive dysfunction |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/987,539 Active US10172908B2 (en) | 2013-07-03 | 2016-01-04 | Method for treating cognitive dysfunction |
Country Status (7)
Country | Link |
---|---|
US (2) | US10172908B2 (en) |
EP (1) | EP3016670A4 (en) |
JP (2) | JP6254692B2 (en) |
CN (1) | CN105873598A (en) |
AU (1) | AU2014284496A1 (en) |
CA (1) | CA2916701A1 (en) |
WO (1) | WO2015002903A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017027848A1 (en) | 2015-08-12 | 2017-02-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier |
ES2930077T3 (en) | 2016-02-15 | 2022-12-07 | Inst Nat Sante Rech Med | Apelin for use in the treatment of postoperative cognitive dysfunction |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955430A (en) | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
DE69435301D1 (en) | 1993-09-24 | 2010-08-26 | Univ Southern California | Use of angiotensin II analogues for tissue repair |
PT730465E (en) | 1993-09-24 | 2002-06-28 | Univ Southern California | UTILIZATION OF ANGIOTENSIN III AND ANALOGS OF THIS IN TISSUE SCISSORING |
US5834432A (en) | 1995-06-06 | 1998-11-10 | The University Of Southern California | Use of angiotensin II Type 2 receptor agonists in tissue repair |
US6110895A (en) | 1996-12-16 | 2000-08-29 | University Of Southern California | Method of promoting healing in skin grafts |
US6335195B1 (en) | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
US6248587B1 (en) | 1997-11-26 | 2001-06-19 | University Of Southern Cailfornia | Method for promoting mesenchymal stem and lineage-specific cell proliferation |
JP4347522B2 (en) | 1997-12-12 | 2009-10-21 | ユニバーシティ オブ サザン カリフォルニア | Wound healing composition |
US6239109B1 (en) | 1998-02-09 | 2001-05-29 | University Of Southern California | Method of promoting erythropoiesis |
US7173011B2 (en) | 2000-11-20 | 2007-02-06 | University Of Southern California | Radiation therapy methods |
US6455500B1 (en) | 1998-03-10 | 2002-09-24 | University Of Southern California | Radiation therapy methods |
AU3077299A (en) | 1998-03-11 | 1999-09-27 | University Of Southern California | Method of promoting production of living tissue equivalents |
US6762167B1 (en) | 1998-05-11 | 2004-07-13 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
WO1999058140A1 (en) | 1998-05-11 | 1999-11-18 | University Of Southern California | Methods to increase white blood cell survival after chemotherapy |
CA2328871C (en) | 1998-07-13 | 2002-10-01 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
US6916783B2 (en) | 1998-07-13 | 2005-07-12 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
WO2000009144A1 (en) | 1998-08-13 | 2000-02-24 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
US6730775B1 (en) | 1999-03-23 | 2004-05-04 | University Of Southern California | Methods for limiting scar and adhesion formation |
US7338938B2 (en) | 1999-05-10 | 2008-03-04 | University Of Southern California | Methods for treating a patient undergoing chemotherapy |
US6821953B1 (en) | 1999-12-16 | 2004-11-23 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
US6747008B1 (en) | 2000-06-19 | 2004-06-08 | University Of Southern California | Methods for treating and preventing alopecia |
AU2001271926A1 (en) | 2000-07-13 | 2002-01-30 | University Of Southern California | Methods for promoting dendritic cell proliferation or differentiation |
US7122523B2 (en) | 2001-05-01 | 2006-10-17 | University Of Southern California | Methods for inhibiting tumor cell proliferation |
BRPI0502497A (en) | 2005-06-28 | 2007-02-06 | Univ Minas Gerais | use of protein-coupled receptor agonists and antagonists, but as modulators of apoptotic activity for the study, prevention and treatment of diseases |
BRPI0613005A8 (en) * | 2005-07-15 | 2017-12-26 | Angiochem Inc | use of aprotinin polypeptides as carriers in pharmaceutical conjugates. |
JP5502480B2 (en) * | 2006-09-18 | 2014-05-28 | コンピュゲン エルティーディー. | Biologically active peptides and methods of use thereof |
US20090104210A1 (en) * | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
US20090227507A1 (en) | 2008-03-10 | 2009-09-10 | University Of Southern California | Angiotensin (1-7) Dosage Forms and Uses Thereof |
EP2603228A1 (en) | 2010-08-10 | 2013-06-19 | The University Of Southern California | Use of angiotensin- ii (1-7) in cell transplantation and as an agent for preventing/treating norovirus infection |
EP2455388A1 (en) * | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
AU2012351939A1 (en) * | 2011-12-16 | 2014-07-10 | Tarix Pharmaceuticals Ltd. | Angiotensins for treatment of fibrosis |
EP2819687A4 (en) | 2012-02-10 | 2015-09-30 | Tarix Pharmaceuticals Ltd | Compositions and methods for treatment of peripheral vascular disease |
EP2849773A1 (en) | 2012-05-14 | 2015-03-25 | University of Southern California | Methods for limiting development of a skin wound |
WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
US20140205631A1 (en) | 2013-01-23 | 2014-07-24 | University Of Southern California | Stimulation of vaccination by angiotensin peptides |
EP2968441A1 (en) | 2013-03-15 | 2016-01-20 | University of Southern California | Methods for treating multiple sclerosis |
ES2650746T3 (en) | 2013-04-30 | 2018-01-22 | University Of Southern California | Accelerated healing of eye lesions using angiotensin peptides |
US20160199436A1 (en) | 2015-01-08 | 2016-07-14 | University of Iowa Research Foudation | Methods and compositions for the treatment of amyotrophic lateral sclerosis |
-
2014
- 2014-06-30 CA CA2916701A patent/CA2916701A1/en not_active Abandoned
- 2014-06-30 AU AU2014284496A patent/AU2014284496A1/en not_active Abandoned
- 2014-06-30 EP EP14820282.3A patent/EP3016670A4/en not_active Withdrawn
- 2014-06-30 CN CN201480038443.8A patent/CN105873598A/en active Pending
- 2014-06-30 JP JP2016524300A patent/JP6254692B2/en active Active
- 2014-06-30 WO PCT/US2014/044962 patent/WO2015002903A1/en active Application Filing
-
2016
- 2016-01-04 US US14/987,539 patent/US10172908B2/en active Active
-
2017
- 2017-11-30 JP JP2017229883A patent/JP2018039840A/en active Pending
-
2018
- 2018-11-13 US US16/189,833 patent/US20190134145A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3016670A4 (en) | 2017-01-18 |
CN105873598A (en) | 2016-08-17 |
CA2916701A1 (en) | 2015-01-08 |
US20160206681A1 (en) | 2016-07-21 |
US10172908B2 (en) | 2019-01-08 |
EP3016670A1 (en) | 2016-05-11 |
AU2014284496A1 (en) | 2016-01-21 |
WO2015002903A1 (en) | 2015-01-08 |
JP2018039840A (en) | 2018-03-15 |
JP2016523921A (en) | 2016-08-12 |
JP6254692B2 (en) | 2017-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1807083B1 (en) | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
US11104706B2 (en) | Ang (1-7) derivative oligopeptides and methods for using and producing the same | |
US7919459B2 (en) | Use of C5a receptor antagonist in the treatment of fibrosis | |
US20100311642A1 (en) | Use of v2 receptor antagonists in combination with vaso pressinergic agnosts | |
US20190134145A1 (en) | Method for treating cognitive dysfunction | |
US20160101117A1 (en) | Use of Megestrol Acetate for Improving Heart Function and the Treatment of Heart Insufficiency | |
US20180221433A1 (en) | Angiotensins in muscular dystrophy | |
BRPI1103387A2 (en) | pharmaceutical composition for the treatment of hypertension based on the co-administration of antihypertensives and angiotensin (1-7) or another receptor agonist but | |
US20180200326A1 (en) | Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments | |
AU2003215446B2 (en) | Use of C5a receptor antagonist in the treatment of fibrosis | |
US20240148735A1 (en) | Methods of treating heart failure with vibegron | |
US20050014675A1 (en) | Cell migration inhibitor | |
Głuszek et al. | Sacubitril/valsartan in therapy of hypertension | |
JPH02172917A (en) | Pharmaceutical preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |